Posters

      Lung Sphingolipidome In A Mouse Model Of Cigarette Smoke-Induced Emphysema

      Phillips, B.; Boue, S.; Veljkovic, E.; Peitsch, M. C.; Hoeng, J.
      Conference date
      Mar 18, 2014
      Conference name
      The 5th International Singapore Lipid Symposium
      Link to more information
      Link to more information
      Topic
      Summary

      Background: Cigarette smoking is the primary cause of Chronic Obstructive Pulmonary Disease (COPD). Sphingolipids have been shown to play important roles in the pathobiology of lung diseases with the effects of ceramide on emphysematous changes amongst the best documented. In addition, sphingosine-1-phosphate (S1P) and S1P receptors have also been characterized as mediators in the pathobiology of fibrosis and acute lung injury. Aim: Using state-of-the-art lipidomics supplemented with physiological and molecular endpoints, we assessed the biological responses in the lungs of C57BL/6 mice switching to a prototype modified risk tobacco product (pMRTP) compared to smoking cessation after an initial exposure to 3R4F reference cigarette smoke (CS). Methods: Detailed lipidomics profiles were obtained from the lungs of C57BL/6 mice, a rodent model susceptible to emphysema. Mice were exposed to mainstream CS, pMRTP, or to fresh air (Sham) for up to seven months, or to pMRTP (Switch) or fresh air (Cessation) for up to five months after an initial CS exposure period of two months. Molecular and histopathological parameters were also investigated to characterize the lung inflammatory response and emphysema at different time points. Results: The findings of the present study link CS-induced pathophysiological changes to alterations in lung lipid metabolism, with major impact on both eicosanoids and on the sphingolipidome. Long chain ceramides, gangliosides, and sphingosine were all affected by CS, with increasing effect over time. Levels of these lipids in mice switching to a pMRTP or to fresh air (Cessation) rapidly returned to those of fresh air-exposed mice. Conclusion: A switch to the pMRTP aerosol after 2 months of cigarette smoke exposure tracked closely with the cessation exposure group in all assessed parameters.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.